Latest Administration News

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Phoslock Environmental Technologies has reversed its cashflow deficits with a quarterly surplus, resumed factory operations after a long pause, and is gearing up for significant sales growth in 2026.

PolyNovo reports a robust 26% increase in group sales for 1H FY26, driven by strong U.S. market expansion and a near tripling of NovoSorb MTX sales. The company also completes a new manufacturing facility, positioning itself for sustained growth.

Buru Energy advances its Rafael Gas Project with strong funding interest and a $2.35 million capital raise, setting the stage for critical 2026 drilling and resource validation.

Astron Limited has responded to an ASX query regarding delayed disclosure of director interest changes, attributing the lapse to administrative oversight and outlining steps to tighten compliance.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

Australian Ethical reported a slight 1% decline in funds under management to $14.08 billion for December 2025, balancing positive retail flows against institutional mandate losses and market headwinds.

Eastern Metals Limited has responded to ASX concerns over delayed disclosure of director interest changes, attributing the lapse to end-of-year administrative challenges while affirming its compliance framework remains robust.

Southern Cross Gold Consolidated Ltd. has achieved a pivotal regulatory milestone enabling underground exploration at its Sunday Creek project, backed by strong drilling results and a robust cash position of $130.4 million.

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

Southern Cross Gold Consolidated Ltd throws its weight behind Australia’s new A$1.2 billion Critical Minerals Strategic Reserve, spotlighting its Sunday Creek gold-antimony project as a key player in securing domestic supply and reducing reliance on China.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.